Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Allergy Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

8 March 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company

specialising in allergy vaccines, today announces that Manuel Llobet, Chief Executive Officer, Nick Wykeman,

Chief Financial Officer, and Alan Bullimore, Head of Business Innovation of Allergy Therapeutics, will present at the Cowen 42nd Annual Health Care Conference taking place from 07-09 March 2022.

The presentation will review data supporting the upcoming clinical trials for the Group's lead pipeline candidates including Grass MATA MPL, which is expected to enter Phase III development in Q3 2022, and VLP Peanut, which is on track to enter the clinic in the Phase I PROTECT trial later this year.   

A replay of the presentation will be made available under the 'Investors' section on Allergy Therapeutics'

website at www.allergytherapeutics.com/investors/results-reports-and-presentations/.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.